Psychedelic drug

Alchemy Community Therapy Center Welcomes New Board Members

Retrieved on: 
Tuesday, December 13, 2022
Psychotherapy, Woman, Emerging, CPA, MHA, Human, Entheogen, MSW, M.A, Social justice, BIPOC, San Francisco Bay Area, Research, CGMA, MPH, Psychedelic drug, Mental health, Pharmaceutical industry, Management, Medicine, Alchemy

OAKLAND, Calif., Dec. 13, 2022 (GLOBE NEWSWIRE) -- The Alchemy Community Therapy Center , a 501(c)(3) non-profit which provides high-quality training and accessible psychedelic therapy to underserved communities, announced today that it has added three new board members, all leaders in the field, effective immediately.

Key Points: 
  • OAKLAND, Calif., Dec. 13, 2022 (GLOBE NEWSWIRE) -- The Alchemy Community Therapy Center , a 501(c)(3) non-profit which provides high-quality training and accessible psychedelic therapy to underserved communities, announced today that it has added three new board members, all leaders in the field, effective immediately.
  • “This is the first time Alchemy has added new board members since its founding,” said Dr. Deidra Somerville, Ph.D., MSW, the organization’s executive director.
  • As its board grows, Alchemy would like to emphasize its gratitude to interim board chair Charlie Bathgate; treasurer Mark Grant, CPA, FINOP, CGMA; secretary Greg Kearns, MHA; and board members Ismail “Izzy” Lourido Ali, J.D.
  • “The new board members are colleagues of the current board, who have contributed to access, equity and innovation in the fields of law, treatment, and training.”
    The Alchemy Community Therapy Center (previously known as the Sage Institute for Psychedelic Therapy) is a sliding scale clinic that offers psychotherapy and psychedelic-assisted therapy (as it becomes legal) to underserved communities in the Bay Area.

PSYC Provides Shareholders with a Year-End Company Review for 2022

Retrieved on: 
Tuesday, December 13, 2022
Acquisition, Nucleus, SMC, Nevada corporation, Sale, Growth, Strategic planning, Research, Mining, Uncertainty, Thought, Community manager, COVID-19, Creativity, EV, Psilocybin, Atmosphere, Health, Omicron, Safety, Education, Multimedia, Debenture, OTCQB, Digital, Conference, BIDS, Management, OTC Markets Group, Technical, News, CFO, Consciousness, Sport, Cannabis, City, Psychedelic drug, Natural Resources, Google Analytics, Map, OTC, Ecosystem, Calendar, Markets.com, Partnership, Holding company, Video game, Creative industries, Security (finance), Mobile phone, Nightclub, Risk management, Audit, Video game console, Retail, Marketing, Bonfire

In February of this year, the Company launched Spotlight Media Corporation (“SMC”), a Nevada corporation and wholly owned subsidiary of PSYC.

Key Points: 
  • In February of this year, the Company launched Spotlight Media Corporation (“SMC”), a Nevada corporation and wholly owned subsidiary of PSYC.
  • In March of this year, the Company secured a $350K private equity-based capital financing deal with Trent Sullivan of Jackson, Tennessee.
  • In July of this year, the Company announced the consolidation of 49 previously issued convertible debentures (“the Debentures”).
  • In August of this year, the Company published its 2021 audited financials helping to provide PSYC with fully audited financials for each of the two most recent fiscal years (2020 & 2021).

Cybin Presents CYB003 Preclinical Data at 2022 American College of Neuropsychopharmacology Annual Meeting

Retrieved on: 
Tuesday, December 6, 2022
Biotechnology, Mental Health, Other Health, Health, Pharmaceutical, Psilocybin, Therapy, NYSE American, United Kingdom, Potential, Food, American College, EDGAR, MBBS, Plasma, Risk, Psychedelic drug, Patient, NEO, Research, DNB, NYSE, Family, Disease, Inc., Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Health Canada, COVID-19, American College of Neuropsychopharmacology, News, Growth, Joint Planning and Development Office, Safety, Engineering, Doctor of Philosophy, Serotonin, Pharmacokinetics, MDD, Pharmaceutical industry, Vitro

Cybin Inc. (NEO:CYBN) (NYSE American: CYBN) (Cybin or the Company), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics, today announced that the Company presented two posters on its deuterated psilocybin analog, CYB003, at the American College of Neuropsychopharmacology (ACNP) annual meeting taking place December 4-7, 2022, in Phoenix, Arizona.

Key Points: 
  • Cybin Inc. (NEO:CYBN) (NYSE American: CYBN) (Cybin or the Company), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics, today announced that the Company presented two posters on its deuterated psilocybin analog, CYB003, at the American College of Neuropsychopharmacology (ACNP) annual meeting taking place December 4-7, 2022, in Phoenix, Arizona.
  • The data presented, including new pharmacokinetics (PK) findings, further strengthen the therapeutic profile of CYB003 as a novel treatment for major depressive disorder (MDD).
  • We were honored to present our data at ACNP amongst leading scientists and academics in neuropsychopharmacology.
  • Compared to classical psilocybin, CYB003 has demonstrated less variability in plasma levels, faster onset of action, shorter duration of effect, and potentially better tolerability.

PSYC Corporation Discusses Its Diversification and Growth Strategy with The Stock Day Podcast

Retrieved on: 
Friday, December 2, 2022
Nevada corporation, Sale, Omicron, COVID-19, Markets.com, City, Mining, SMC, Cannabis, Health, News, Sport, Psychedelic drug, Research, Psilocybin, Creativity, FDA, OTC, OTCQB, Interview, Acquisition, OTC Markets Group, Uncertainty, BIDS, Education, Auction, Video game

CEO of the Company, David Flores, joined Stock Day host Everett Jolly.

Key Points: 
  • CEO of the Company, David Flores, joined Stock Day host Everett Jolly.
  • "We have seen a substantial uptick in incoming revenue here with both of these platforms, which is great news for us."
  • "We are absolutely demonstrating that we do have a very solid monetization plan in place," continued Flores.
  • Spotlight Media Corporation ("SMC") ( www.spotlightmediacorp.com ) is a Nevada Corporation and is a privately held wholly owned subsidiary of PSYC that was incorporated on February 8, 2022.

Mindset Pharma and PharmAla Enter into Exclusive Sales Agreement for the Sale and Distribution of Pharmaceutical Grade Psilocybin

Retrieved on: 
Wednesday, November 16, 2022
Otsuka Pharmaceutical, Partnership, FSE, CGMP, Research, Therapy, Psilocybin, Development, CSE, MSET, DEA, Drug discovery, MDMA, Pharmaceutical industry, Fine chemical, MDXX, Psychedelic drug, Mindset

Under the sales agreement, PharmAla will be the exclusive global reseller of Mindsets cGMP (i.e.

Key Points: 
  • Under the sales agreement, PharmAla will be the exclusive global reseller of Mindsets cGMP (i.e.
  • In addition to forging new ground in next generation psychedelic drug discovery, Mindset has also developed a patent-pending, highly scalable psilocybin synthesis technology.
  • We have chosen PharmAla as a partner because of their track record in working with clinical researchers, and existing sales infrastructure to sell pharmaceutical grade psychedelic compounds.
  • Mindset was established in order to develop next-generation pharmaceutical assets that leverage the breakthrough therapeutic potential of psychedelic drugs.

Mindset Pharma and PharmAla Biotech Enter into Exclusive Sales Agreement

Retrieved on: 
Wednesday, November 16, 2022
Otsuka Pharmaceutical, Partnership, FSE, CGMP, GMP, Research, Therapy, Psilocybin, Development, CSE, MSET, DEA, Drug discovery, MDMA, Pharmaceutical industry, Fine chemical, Online shopping, MDXX, Psychedelic drug, Mindset

Under the sales agreement, PharmAla will be the exclusive global reseller of Mindsets cGMP (i.e.

Key Points: 
  • Under the sales agreement, PharmAla will be the exclusive global reseller of Mindsets cGMP (i.e.
  • In addition to forging new ground in next generation psychedelic drug discovery, Mindset has also developed a patent-pending, highly scalable psilocybin synthesis technology.
  • We have chosen PharmAla as a partner because of their track record in working with clinical researchers, and existing sales infrastructure to sell pharmaceutical grade psychedelic compounds.
  • PharmAla Biotech Holdings Inc. (CSE: MDMA) is a biotechnology company focused on the research, development, and manufacturing of MDXX class molecules, including MDMA.

Cybin Inc. Presents CYB003 Preclinical Data at Neuroscience 2022

Retrieved on: 
Tuesday, November 15, 2022
Biotechnology, Mental Health, Other Health, Health, Pharmaceutical, Psilocybin, Inc., Pharmacokinetics, Serotonin, United Kingdom, NYSE American, Plasma, News, Risk, Potential, Engineering, Therapy, Drug discovery, NYSE, Health Canada, Research, Safety, Society, SFN, Disease, Growth, EDGAR, COVID-19, Family, Psychedelic drug, Food, NEO, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Patient, Pharmaceutical industry, Neuroscience

Cybin Inc. (NEO:CYBN) (NYSE American: CYBN) (Cybin or the Company), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics, today announced that the Company presented a poster highlighting preclinical data for its deuterated psilocybin analog, CYB003 at Neuroscience 2022 hosted by the Society for Neuroscience (SFN) taking place November 12-16, 2022, in San Diego, CA.

Key Points: 
  • Cybin Inc. (NEO:CYBN) (NYSE American: CYBN) (Cybin or the Company), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics, today announced that the Company presented a poster highlighting preclinical data for its deuterated psilocybin analog, CYB003 at Neuroscience 2022 hosted by the Society for Neuroscience (SFN) taking place November 12-16, 2022, in San Diego, CA.
  • Our presentation at Neuroscience 2022 highlighted the findings from our CYB003 preclinical studies.
  • Compared to classical psilocybin, CYB003 has demonstrated less variability in plasma levels, faster onset of action, and shorter duration of effect.
  • CYB003 is currently being evaluated in a Phase 1/2a clinical trial for the treatment of major depressive disorder.

Cybin Inc. Reports Second Quarter Financial Results and Recent Business Highlights

Retrieved on: 
Monday, November 14, 2022
Biotechnology, Mental Health, Health, Pharmaceutical, Clinical Trials, Trial of the century, IP, Engineering, ATM, Patent, Safety, Disease, Growth, Plasma, MDD, NYSE American, PK, News, Drug development, Health Canada, Research, Neuropharmacology, Nature, Excretion, Intellectual property, EDGAR, COVID-19, Business, Psilocybin, Metabolism, Psychedelic drug, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Sale, Inc., United Kingdom, Therapy, DMT, Pharmacokinetics, Cerebral cortex, Hemodynamics, Drug discovery, Food, NEO, Knowledge, Catalog, Calendar, Risk, Anxiety, NYSE, PD, USD, Patient, Renewable energy, Pharmaceutical industry, Risk management, Absorption, Kernel

Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (Cybin or the Company), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics, today reported unaudited financial results for its second quarter ended September 30, 2022, and recent business highlights.

Key Points: 
  • Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (Cybin or the Company), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics, today reported unaudited financial results for its second quarter ended September 30, 2022, and recent business highlights.
  • Depending on market conditions, this will allow Cybin to access additional cash for growth opportunities and working capital.
  • Recent Business and Pipeline Highlights:
    Reported progress update on CYB004-E Phase 1 trial.
  • Collectively, Cybin now has access to more than 35 patents and applications through a combination of internal filings and licensing arrangements.

Cybin Provides Progress Update on its CYB004-E Phase 1 Trial

Retrieved on: 
Thursday, November 10, 2022
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, NYSE American, NYSE, Psilocybin, Risk, Food, Knowledge, Research, EDGAR, Eye, DMT, Health Canada, COVID-19, NEO, Therapy, United Kingdom, News, Goal, Safety, U.S. Securities and Exchange Commission, Time, Inc., Pharmacokinetics, Company, Drug development, Disease, Program, Anxiety, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Engineering, Psychedelic drug, Patient, Growth, Acquisition, Pharmaceutical industry, Risk management

The CYB004-E Phase 1 trial was acquired from Entheon Biomedical Corp. (Entheon) in July 2022.

Key Points: 
  • The CYB004-E Phase 1 trial was acquired from Entheon Biomedical Corp. (Entheon) in July 2022.
  • The acquisition of the Phase 1 DMT study was done with an eye toward informing and accelerating the clinical path forward for CYB004 and we are very pleased with the progress so far.
  • The CYB004-E trial is ongoing at the Centre for Human Drug Research in the Netherlands and is the Companys largest Phase 1 DMT trial conducted to date.
  • Cybin expects the Phase 1 trial to be completed in the first half of 2023i.

Cybin to Participate in the Jefferies London Healthcare Conference and Upcoming Investor Events

Retrieved on: 
Thursday, November 3, 2022
Biotechnology, Pharmaceutical, Health, Company, Therapy, Industry, Inc., NYSE, Webcast, Event, Engineering, Psychedelic drug, Patient, GMT, United Kingdom, NEO, Pharmaceutical industry

Mr. Drysdale will participate in a panel discussion titled Psychedelics Landscape What can we expect?

Key Points: 
  • Mr. Drysdale will participate in a panel discussion titled Psychedelics Landscape What can we expect?
  • PSYCH Investor Event: Emerging Innovations in Psychedelic Healthcare, November 17, 2022, in London, UK
    Mr. Drysdale will participate in a live fireside chat at 5:00 p.m. GMT with other industry thought leaders.
  • The live and archived webcasts will also be available on the Companys investor relations website on the Events & Presentations page.
  • Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland.